Status:
UNKNOWN
A China RWS to Evaluate the Effectiveness and Safety of Perampanel as an add-on Treatment for Epileptic Seizure
Lead Sponsor:
Beijing Children's Hospital
Conditions:
Epilepsy
Eligibility:
All Genders
Brief Summary
This study is a real-word clinical trial. The purpose of this study is to evaluate the effectiveness and safety of perampanel as an add-on treatment for epileptic seizure. The enrolled subjects were e...
Detailed Description
This is a multi-center, prospective, observational study. Subjects who meet all of the inclusion and none of the exclusion criteria will be received perampanel. Baseline seizure counts (frequency) dat...
Eligibility Criteria
Inclusion
- Within 1 year before taking perampanel, the frequency of epileptic seizures was ≥1 time/month on average;
- 1-3 kinds of AEDs have been used, and the optimal dose and course of treatment have been reached, but the effect is not good. Perampanel is used as an additional treatment;
- Follow up for at least 3 months;
- Sign informed consent (if necessary).
Exclusion
- Patients who have participated in other researches on antiepileptic drugs or medical devices;
- Inaccurate or unreliable clinical records according to the judgment of participating doctors;
- When the database is closed, the expected follow-up time is less than 6 months.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05257915
Start Date
January 1 2021
End Date
June 30 2022
Last Update
February 25 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100045
2
Beijing TianTan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
3
Beijing University First Hospital
Beijing, Beijing Municipality, China
4
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China